Novel "second-generation" approaches for the control of type 2 diabetes.
Rotella
David P
DP
Lexicon Pharmaceuticals, 350 Carter Road, Princeton, New Jersey 08540, USA. drotella@lexpharma.com
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D005934:Glucagon / Q000494:pharmacology / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011498:Protein Precursors / Q000494:pharmacology / Q000627:therapeutic use; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists; D014157:Transcription Factors / Q000819:agonists
D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D011480:Protease Inhibitors; D011498:Protein Precursors; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; C516607:PTPN1 protein, human; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases; D018819:Dipeptidyl Peptidase 4